Gaya Herald

Glaucoma Pipeline Assessment | 70+ Companies & 70+ Drugs | DelveInsight

 Breaking News
  • No posts were found

Glaucoma Pipeline Assessment | 70+ Companies & 70+ Drugs | DelveInsight

November 30
02:32 2022
Glaucoma Pipeline Assessment | 70+ Companies & 70+ Drugs | DelveInsight

DelveInsight’s, “Glaucoma Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Recent Developmental Activities in the Glaucoma Pipeline

  • In August 2022Alcon agreed to acquire Aerie Pharmaceuticals for about $770 million, betting its sprawling commercial presence can boost the uptake of the biotechnology company’s two glaucoma drugs. The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline. Alcon will pay $15.25 for each share of Aerie, a 37% premium to the stock’s closing price.
  • In March 2022Oculis S.A. and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. The agreement supports Oculis’s mission to become a global ophthalmology leader bringing breakthrough innovations to the top three segments of the market: retina, dry eye and glaucoma.
  • In February 2022Ocular Therapeutix presented interim Phase I data for OTX-TIC, highlighting the product candidate’s ability to cause a clinically meaningful decrease in intraocular pressure (IOP) for six months or longer with a single implant in many subjects while preserving corneal health. The Company is actively enrolling its US-based Phase II prospective, multi-center, randomized, controlled clinical trial evaluating the safety, tolerability, and efficacy of OTX-TIC for the treatment of patients with primary open-angle glaucoma or ocular hypertension.
  • AM008 is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye with a target duration of drug delivery of four to six months. AM008 is in development for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. In a Phase I clinical trial, all cohorts experienced a mean reduction in IOP from a baseline of 7-11 mmHg with the onset of action as early as two days after insertion. Many subjects across the four cohorts demonstrated durability of activity of 6 months or longer with a single implant. Overall, no serious ocular adverse events were noted. AM008 is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant.
  • NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop, designed to release bimatoprost and NO into the eye to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. NCX 470 is currently in two multi-regional Phase III clinical trials. NCX 470 is covered worldwide until 2029 under a composition of matter patent with potential extension up to 5 years in the US and EU and a formulation patent until 2039 in the US, EU, Japan and China.
  • Sun Pharma Advanced Research Company (SPARC) reported positive top-line results from its Phase III trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension. The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1 percent dosed three times a day.

 

Key takeaways from the Glaucoma Pipeline Report

  • DelveInsight’s Glaucoma Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
  • The Glaucoma pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
  • Glaucoma Pipeline Companies include Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,  HK inno.N, Avirmax Inc., and many others.
  • Glaucoma Pipeline Therapies include QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 / BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010, and many others.

 

Request a sample and discover the recent advances in glaucoma treatment drugs @ Glaucoma Pipeline Report

 

Glaucoma Overview

A glaucoma is a group of eye diseases causing optic nerve damage. The optic nerve carries images from the retina, which is the specialized light sensing tissue, to the brain so we can see. In glaucoma, eye pressure plays a role in damaging the delicate nerve fibers of the optic nerve. When a significant number of nerve fibers are damaged, blind spots develop in the field of vision. Once nerve damage and visual loss occur, it is permanent. Most people don’t notice these blind areas until much of the optic nerve damage has already occurred. If the entire nerve is destroyed, blindness results. Glaucoma is a leading cause of blindness in the world, especially in older people.

Early detection and treatment by your ophthalmologist are the keys to preventing optic nerve damage and vision loss from glaucoma. The exact causes of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Although high eye pressure sometimes leads to glaucoma, many people can also develop glaucoma with “”normal”” eye pressure. The treatment for glaucoma depends upon the nature and severity of each case. In general, glaucoma cannot be cured, but it can be controlled. Eye drops, pills, laser procedures, and surgical operations are used to prevent or slow further damage from occurring. With any type of glaucoma, regular eye examinations are very important to detect progression and to prevent vision loss.

 

Glaucoma Emerging Drugs Profile

  • QLS-101: Qlaris Bio, Inc.
  • NCX 470: Nicox

 

Glaucoma Pipeline Insight Report

“Glaucoma – Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glaucoma pipeline landscape is provided which includes the disease overview and Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Find out more about glaucoma treatment drugs @ Glaucoma Clinical Trials Analysis

 

DelveInsight’s Glaucoma Pipeline report covers around 70+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Glaucoma Pipeline Therapeutics Analysis

There are approx. 70+ key companies which are developing therapies for Glaucoma. The companies which have their Glaucoma drug candidates in the most advanced stage, i.e. phase III include, Nicox.

 

Glaucoma Pipeline development activities

The Glaucoma pipeline report provides insights into:

  • All of the companies that are developing therapies for the treatment of Glaucoma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Glaucoma
  • Glaucoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of M Glaucoma

The Glaucoma Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Request for Sample PDF Report to know more about glaucoma Drugs and therapies – Glaucoma Treatment Landscape

 

Scope of the Glaucoma Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Inhalation, Parenteral, Intranasal, Intravenous, Oral, Subcutaneous
  • Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
  • Therapeutics Assessment By Mechanism of Action: KATP channel modulators, Nitric oxide donors, Protein kinase inhibitors, Carbonic anhydrase inhibitors, Prostaglandin F2 alpha agonists, Antioxidants, Electron transport chain complex protein modulators, TIE-2 receptor modulators, Cannabinoid receptor agonists
  • Key Glaucoma Companies: Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,  HK inno.N, Avirmax Inc., and others.
  • Key Glaucoma Pipeline Therapies: QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 / BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010,  and others.

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glaucoma: Overview
  4. Glaucoma Pipeline Therapeutics
  5. Glaucoma Therapeutic Assessment
  6. Glaucoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NCX 470: Nicox
  9. Mid Stage Products (Phase II)
  10. QLS-101: Qlaris Bio, Inc.
  11. Early Stage Products (Phase I)
  12. ONL 1204: ONL Therapeutics
  13. Preclinical and Discovery Stage Products
  14. RTC 1119: Ripple Therapeutics
  15. Inactive Products
  16. Glaucoma Key Companies
  17. Glaucoma Key Products
  18. Glaucoma- Unmet Needs
  19. Glaucoma- Market Drivers and Barriers
  20. Glaucoma- Future Perspectives and Conclusion
  21. Glaucoma Analyst Views
  22. Glaucoma Key Companies
  23. Appendix

 

Download Sample PDF Report for Glaucoma clinical trials advancements @ Glaucoma Emerging Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/